
    
      After informed consent is signed, this study will involve 1) collection of basic HCT data and
      clinical data available in the medical record and 2) providing blood (and saliva in
      occasional cases) samples for processing, storage, DNA extraction, and analysis (including a
      seven biomarker protein panel as well as future unspecified research purposes).

      Pediatric and adult patients will be included (all adult patients will be from the Fred
      Hutchinson Cancer Research Center, the Johns Hopkins Sidney Kimmel Comprehensive Cancer
      Center, and the Indiana University Simon Cancer Center).

      Primary Objective:

      1. To confirm that ST2 alone or the seven-biomarker panel measured at initiation of GVHD
      therapy predict a) D180 post-therapy non-relapse mortality; b) D28 post-therapy non-response,
      and c) GVHD grade 1-4 onset D180 post-therapy non-relapse mortality.

      Secondary Objective:

        1. To demonstrate that ST2 alone or the seven-biomarker panel measured at day 14 or day 21
           post-HCT (or a combination of these time points) predicts D180 post-HCT non-relapse
           mortality.

        2. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of
           GVHD symptoms/therapy diagnose acute GVHD as compared to other complications presenting
           with similar symptoms (drug rash, CMV, Clostridium enteritis).

        3. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of
           GVHD symptoms/therapy diagnose the severity of acute GVHD at onset and maximum.

        4. To develop a repository of biospecimens linked to clinical data for future unspecified
           research.
    
  